Last reviewed · How we verify
Arixtra
At a glance
| Generic name | Arixtra |
|---|---|
| Sponsor | LifeBridge Health |
| Target | Antithrombin-III, Coagulation factor X |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Approved indications
- Deep venous thrombosis
- Prevention of deep vein thrombosis
- Pulmonary thromboembolism
Common side effects
- Major bleeding
- Minor bleeding
- Bleeding
- Hemorrhage
- Anemia
- Insomnia
- Increased wound drainage
- Hypokalemia
- Dizziness
- Hypotension
- Confusion
- Bullous eruption
Key clinical trials
- Intravenous Immunoglobulin for the Treatment of Acute Exacerbations of Idiopathic Pulmonary Fibrosis (PHASE3)
- Thromboprophylaxis in Lower Limb Immobilisation (PHASE3)
- Hip Fracture Surgery Arterial and Venous Thrombotic Events Prevention (PHASE3)
- Treatment With Aspirin Alone Versus Aspirin in Combination With Fondaparinux Before Early Coronary Assessment in Patients With Non-ST-Elevation Myocardial Infarction (PHASE4)
- Hokusai Study in Pediatric Patients With Confirmed Venous Thromboembolism (VTE) (PHASE3)
- Coagulopathy of COVID-19: A Pragmatic Randomized Controlled Trial of Therapeutic Anticoagulation Versus Standard Care (PHASE3)
- Management of Atrial Fibrillation in Patients With Cancer (MAFIC Study)
- Multicentric Prospective Validation of a Universal Test to Quantify Apixaban, Rivaroxaban, Danaparoid and Fondaparinux Levels
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Arixtra CI brief — competitive landscape report
- Arixtra updates RSS · CI watch RSS
- LifeBridge Health portfolio CI